相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Gronchi et al.
ANNALS OF ONCOLOGY (2021)
Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sarcomas
Georgios Kantidakis et al.
EUROPEAN JOURNAL OF CANCER (2021)
Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors-A Sarcoma Reference Center Experience
Pawel Sobczuk et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019
Gillian Gresham et al.
JAMA NETWORK OPEN (2020)
Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation
Kazuhiro Tanaka et al.
BMC CANCER (2019)
Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma
P. Dutton et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2018)
The changing landscape of phase II/III metastatic sarcoma clinical trialsanalysis of ClinicalTrials.gov
Y. Que et al.
BMC CANCER (2018)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Surrogates for Survival or Other End Points in Oncology
Michael LeBlanc et al.
JAMA ONCOLOGY (2016)
Innovative research methods for studying treatments for rare diseases: methodological review
Joshua J. Gagne et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Activity endpoints reported in soft tissue sarcoma phase II trials: Quality of reported endpoints and correlation with overall survival
Nicolas Penel et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Clinical Trials in Rare Disease: Challenges and Opportunities
Erika F. Augustine et al.
JOURNAL OF CHILD NEUROLOGY (2013)
Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial Results
Pilar Sune et al.
PLOS ONE (2013)
Quality of Randomized Controlled Trials Reporting in the Treatment of Sarcomas
Maud Toulmonde et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical research for rare disease: Opportunities, challenges, and solutions
Robert C. Griggs et al.
MOLECULAR GENETICS AND METABOLISM (2009)
Other endpoints in screening studies for soft tissue sarcomas
Jaap Verweij
ONCOLOGIST (2008)
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
M Van Glabbeke et al.
EUROPEAN JOURNAL OF CANCER (2002)
Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint
R Mick et al.
CONTROLLED CLINICAL TRIALS (2000)
分享论文
